Minimal Stimulation or Clomiphene Citrate in Treatment of Polycystic Ovary Syndrome

Mansoura University113 enrolled

Overview

The purpose of this study is to compare and determine the the efficacy of minimal stimulation and clomiphene citrate(CC) as the first-line treatment in infertile women with Polycystic Ovary Syndrome(PCOS).

All patients received 100 mg CC (Clomid®; Global Napi Pharmaceuticals, Cairo, Egypt) for 5 days starting from day 3 of spontaneous or induced menstruation. In group A (minimal stimulation), 2 vials of highly purified uFSH , 150 IU (Fostimon; IBSA, Lugano, Switzerland, 75 IU/vial) were given IM on cycle day 9. A total of 3 cycles was offered to each group.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

113

Conditions

Polycystic Ovary Syndrome

Interventions

clomiphene citrate +highly purified uFSHDRUG

clomiphene citrateDRUG

Eligibility

Sex: FEMALEMin age: 20 YearsMax age: 39 Years

Medical Language ↔ Plain English

Inclusion Criteria: * PCOS * No other infertility factors * No previous use of ovarian stimulation drugs Exclusion Criteria: * Congenital adrenal hyperplasia * Cushing syndrome * Androgen secreting tumors

Locations (1)

Mansoura University Hospitals,OB/GYN department

Al Mansurah, Dakahlia Governorate, Egypt

Outcomes

Primary Outcomes

clinical pregnancy rate per cycle

Secondary Outcomes

endometrial thickness at the time of hCG administration

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.